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ABSTRACT 
 
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B 
lymphocytes in blood, bone marrow and lymphoid tissues. The clinical course for the individual 
patient is still unpredictable despite decades of research on prognostic markers and staging 
systems. The aim of this thesis was to review the value of existing prognostic tools in order to 
develop new clinical prognostic markers for CLL and to assess the impact of clonal evolution 
and transformation in CLL in relation to biological markers and given therapy. 
 Paper I: This is a long-term follow-up of the first trial of subcutaneous alemtuzumab as first-
line therapy in CLL. In order to assess duration of response, infectious complications and 
incidence of Richter transformation, a comparison was made with historical controls. Median 
time to treatment failure was 28 months for the alemtuzumab-treated patients compared to 17 
months for the control group (not significant). Infectious complications were not more common 
in the alemtuzumab-treated patients despite profound and prolonged T-cell suppression. The 
rate of Richter transformation was similar between the groups. 
 Paper II: Clinical data of 77 patients included in five phase II trials at Karolinska University 
Hospital were analyzed to find out whether the use of computed tomography (CT) could add 
prognostic information to the Rai and Binet clinical staging systems. A high nodal tumor 
burden evaluated by CT correlated with a shorter time to next therapy and a trend towards 
shorter survival. Massive splenomegaly was associated with shorter overall survival and 
therapy-free survival. 
 Paper III: The expression of the estrogen receptors (ER) α, β1 and its splice variant β2 was 
evaluated in peripheral blood mononuclear cells (PBMC) from CLL patients and normal 
controls using immunocytochemistry. The expression of ERα was generally low whereas most 
PBMCs expressed ERβ1 in both patients and controls. ERβ2 expression was significantly more 
common in CLL. Patients with high expression (> 50% of PBMC) of ERβ1 and/or ERβ2 were 
more likely to need therapy during follow-up. 
 Paper IV: Paraffin-embedded splenic tissue samples were obtained from 62 patients with 
CLL or SLL to assess whether chromosomal aberrations in the spleen have a prognostic impact. 
The cytogenetic abnormalities 11q-, 13q-, 17p- and trisomy 12 were assessed by interphase 
FISH and compared with samples from blood and/or bone marrow. Patients with 11q- and 17p- 
deletions in the spleen had significantly shorter overall and therapy-free survival. Clonal 
evolution seemed to occur in some cases. 
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1 CHRONIC LYMPHOCYTIC LEUKEMIA 
 
1.1 INTRODUCTION 
 
CLL is the most common chronic leukemia in the western world and is characterized 
by the accumulation of small mature appearing B lymphocytes in blood, bone marrow 
and lymphoid tissues [1]. In Sweden around 500 patients are diagnosed with CLL each 
year [2]. The median age at diagnosis is 72 years. 
CLL is incurable with the therapeutic regimens currently in use except for the small 
minority of patients who are suitable for allogenic stem cell transplantation. The 
clinical course in CLL is extremely variable ranging from a stable disease over decades 
to a rapidly progressive disease despite intensive chemoimmunotherapy. 
 
1.2  HISTORY 
 
The term leukemia, “weisses blut” was first coined by Virchow in 1847 [3]. During the 
late 19th century enhanced staining techniques made it possible to separate different 
types of leukemia and in 1903 criteria for the diagnosis of chronic lymphocytic 
leukemia (CLL) were published [4]. However due to lack of accurate 
immunophenotyping, CLL could not be distinguished from other leukemic lymphomas. 
With the recognition of the antigens CD5 and CD23 a unique CLL phenotype could be 
defined. [5] 
 
1.3 ETIOLOGY AND EPIDEMIOLOGY 
 
Predisposing factors for CLL development remains largely unknown. Known 
carcinogenic agents such as tobacco smoke, ionizing radiation and chemical 
compounds appears to have little or no role in CLL. Some rather weak associations 
with pesticides, farming, animal breeding and magnetic fields have been published 
[6-8].  
CLL incidence varies considerably throughout the world and is most common in 
countries with large populations of European descent, whereas the lowest incidence 
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can be found in sub-Saharan Africa and south-east Asia. Japan is the country with the 
lowest recorded CLL rate. In contrast to studies of breast and colon cancer incidence, 
Asians who have migrated to the United States do not have a higher incidence of CLL 
[9,10].  
There is a male predominance in CLL with a ratio of 1.8:1. Women have a better 
prognosis independent of age and stage of disease [11,12]. Most cases are sporadic, but 
there is strong support for a genetic component in CLL, as relatives to  CLL patients 
have an eightfold increased risk to develop CLL [13]. In recent years, the hypothesis 
that an antigen-driven process contributes to CLL development has been supported by 
experimental data [14]. 
 
1.4 DEFINITION OF CLL AND MONOCLONAL B CELL LYMPHOCYTOSIS 
 
According to the iwCLL guidelines, CLL is defined as clonal B-lymphocytosis in 
blood (at least 5 x 109 lymphocytes/L) with a typical phenotype (CD5+, CD19+, 
CD20dim+, CD23+) [15]. In some healthy persons, small clonal B cell populations 
that phenotypically and cytogenetically resemble CLL can be detected [16]. This 
condition has been coined monoclonal B-cell lymphocytosis (MBL) or monoclonal 
lymphocytosis of undetermined significance (MLUS), in analogy with monoclonal 
gammopathy of undetermined significance (MGUS) [17]. The exact distinction 
between these mostly benign conditions and CLL is not biologically evident. A 
diagnosis of MBL requires fewer than 5 x 109 clonal B cells/L and no evidence of 
tissue involvement. MBL frequency increases with age, being virtually undetectable 
under 40 years of age but is present in 50-75% in people older than 90 years [18]. 
MBL is more common in first-degree relatives to patients with CLL [19]. A 
population-based prospective study using prediagnostic frozen samples shows that 
CLL is generally preceded by MBL [20].  
Cases that present without lymphocytosis but with lymphadenopathy, splenomegaly 
and/or bone marrow involvement of clonal B lymphocytes with a typical CLL 
phenotype are classified as small lymphocytic lymphoma (SLL), a condition not 
distinguished from CLL in the current WHO classification guidelines [21]. In a large 
study, similar prognostic factors in CLL and SLL corresponded to a shorter survival 
[22]. 
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1.5 BIOLOGY AND PATHOGENESIS 
 
CLL cells resemble mature lymphocytes and have undergone rearrangement of the 
immunoglobulin genes. The cellular origin has not been clarified [23], but current 
evidence supports that CLL evolves from an antigen-experienced B cell.  
The ability of the human immune system to create antibodies against a vast array of 
antigens is dependent on the B cell diversity created by the recombination of the 
V(D)J gene recombinations of the Ig loci. To further fine-tune the B cell response, 
somatic hypermutation (SHM) occurs during the maturation of the B cell. For many 
years, all CLL cases were thought to have mutated IGHV genes, but in the late 1990s 
it was shown that about 50% of CLL cases were unmutated [24]. Unmutated cases 
have IGHV genes with less than 2% somatic mutations and have a worse prognosis 
[25,26]. 
There is strong evidence that mutated CLL cells are derived from post-germinal center 
(GC) memory B cells which have encountered antigens [1]. Unmutated and mutated 
cases have a common characteristic gene expression signature [27,28], supporting the 
hypothesis that unmutated CLL also stems from antigen-experienced B cells. 
Nevertheless a distinct set of genes is differentially expressed in the two subtypes 
including zeta-chain-associated protein kinase 70 (ZAP-70) and lipoprotein lipase 
(LPL), both more expressed in unmutated cases [29,30]. In the gene expression study 
by Klein et al [27], most of the genes specifically expressed (or overexpressed) in CLL 
are involved in signal transduction pathways but Ror-1, an orphan tyrosine kinase 
receptor, is also highly expressed. Downregulated genes in CLL are, among others 
cyclin B and dihydrofolate reductase, mainly involved in cell cycle progression and 
metabolism, reflecting the quiescent phenotype of most CLL cells. 
 
1.6 CHROMOSOMAL ABERRATIONS, GENE MUTATIONS AND CLONAL 
EVOLUTION 
 
The first studies on chromosomal aberrations in CLL used karyotyping methods. Due 
to the low mitotic activity of CLL cells in blood, cytogenetic abnormalities could only 
be found in 40 to 50% of the cases, the most common being trisomy 12 and deletion 
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of 13q [31]. New stimulating techniques to enhance metaphase cultivation have been 
developed, but are not yet in use in the routine clinical setting [32].  
With interphase FISH on non-stimulated, non-dividing cells, recurrent genomic 
aberrations can be found in more than 80% of CLL cases [33], the most common 
being deletions in chromosome 13q, 11q or 17p and trisomy 12. 
Deletion of 13q14 is found in about 50% of CLL cases. The minimally deleted region 
(MDR) involves two microRNAs (miRs); 15a and 16-1. Both these miRs have a nine 
base pair long nucleotide sequence that is complementary to the mRNA encoding the 
anti-apoptotic protein Bcl-2 [34]. This protein is upregulated in CLL and critical for 
tumor cell survival [35]. The expression of Bcl-2 is inhibited by interactions of miR-
15a/16-1 with Bcl-2 transcripts; deletion of 13q14 can thus indirectly lead to 
increased expression of Bcl-2.    
Deletion of the 11q22-q23 region encompasses the ATM (Ataxia telangiectasia-
mutated) tumor suppressor gene; a central component of the DNA damage response 
pathway to double-strand breaks [36]. This deletion is present in about 20% of CLL 
cases. 
Deletion of 17p13 affects the tumor suppressor gene TP53, which encodes the protein 
p53, a transcription factor critical for DNA damage repair and promotion of apoptosis 
after genotoxic stress [37]. This deletion is uncommon in early-stage disease, but 
more frequent in refractory CLL, affecting 4% and 31% of cases, respectively [1]. 
Cases with deletion of 17p frequently have mutations that inactivate TP53 on the 
other allele [38].  
Trisomy 12 was the first recurrent abnormality described in CLL [39], present in 20% 
of CLL cases. The genes on chromosome 12 of potential importance for CLL 
pathogenesis are largely unknown, but CLLU1, a gene located at 12q22, has been 
shown to be uniquely overexpressed in CLL, even in cases without trisomy 12 [40]. 
Clonal evolution (CE) is defined as the accumulation or acquisition of genomic 
aberrations over time. Previous studies have shown that this occurs in a low 
frequency in CLL [41-43]. CE is more common in ZAP-70-positive and/or unmutated 
CLL [44].   
An unusual feature of CLL is abnormally short telomeres despite the low proliferation 
of most CLL cells [45] and telomere length has shown to be a prognostic marker [46]. 
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1.7 EPIGENETICS IN CLL 
 
Aberrant DNA methylation has been shown to have a strong role in tumorigenesis, with 
genome-wide hypomethylation and regional hypermethylation of tumor suppressor 
gene promoters [47]. One study using genome-wide methylation analysis in CLL 
showed that 2% to 8% of cytosine-phosphoguanine dinucleotide (CpG) islands were 
aberrantly methylated compared with normal controls [48]. A strong correlation 
between promoter methylation and transcriptional silencing has been shown for certain 
individual gene promoters in CLL, for example death-associated protein kinase 1 
(DAPK1) and ZAP-70 [49,50]. Methylation profiles have been shown to vary between 
different prognostic subsets of CLL [51]. 
 
1.8 MICROENVIRONMENT 
 
CLL cells are long-lived in vivo compared to normal B cells [23], but rapidly undergo 
apoptosis in vitro unless co-cultivated with monocyte-derived nurse-like cells (NLC) or 
bone marrow stromal cells [52,53]. The apoptotic resistance in CLL is thus dependent 
on external factors rather than being an intrinsic attribute [54,55]. The view that CLL 
consists mainly of slowly accumulating cell arrested in G0/G1 phase has been 
challenged by an in vivo labelling study of CLL cells [56]. The results showed a higher 
cell turnover than expected and patients with high cell birth rates were more likely to 
have active or progressive disease. A high amount of CLL cells in S-phase has been 
shown to be associated with a short therapy-free and overall survival [57].  
Proliferation centers (PC) have mainly been recognized in spleen and lymph nodes [58-
60], in which a fraction of the CLL cells divide. In the PCs, the malignant lymphocytes 
are in contact with CD3+ T cells (mainly CD3+, CD4+ T cells), that express the CD40 
ligand (CD40L) and support the growth of CLL cells through ligation of CD40, a 
member of the TNF receptor super family highly expressed in CLL [61]. Data supports 
that NF-κB activation of CLL cells also takes place in PCs [62]. 
CLL cells are not just passive bystanders in the microenvironment but can actively 
create a suitable microenvironment by secreting chemokines such as CCL3, CCL4 and 
CCL22 [63,64]. In addition CLL cells express functional CXCR3, CXCR4 and CXCR5 
chemokine receptors that direct neoplastic cell chemotaxis in vitro [65]. Thus the CLL 
microenvironment is likely created by a dynamic interplay between neoplastic and 
normal bystander cells [66]. 
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1.9 ANTIGENS AND MUTATIONAL STATUS IN CLL 
 
There is a bias toward usage of certain Ig gene segments in CLL, in particular 
IGHV1-69, IGHV4-34, IGHV3-7, and IGHV3-21 [24,67]. Patients with CLL cells 
that use IGHV3-21 have relatively aggressive disease, even when mutated [68].  
Some CLL cases share B cell receptors (BCRs) of remarkably similar amino acid 
sequence. These "stereotyped" BCRs exhibit highly homologous HCDR3s, often 
encoded by identical IGHV, IGHD, and IGHJ segments. Furthermore, many 
stereotyped BCRs use the same IGKV or IGLV. Thus the KCDR3s/LCDR3s are very 
similar in protein structure. The likelihood that these similar rearrangements could 
have occurred by chance is extremely remote (< 1 x 10–6 to < 1 x 10–12). Stereotyped 
receptors can be found in approximately 30% of CLL cases, and is more common in 
unmutated CLL [69,70]. The antigen specificities of CLL BCRs are often skewed 
towards polyreactivity, which permits binding to autoantigens as well as exoantigens 
[14,71]. Interestingly, there is molecular evidence for a link between persistence of 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) and usage of a specific 
stereotyped IGVH 4-34 receptor [72].  
These findings suggest that antigen selection may play an important role in CLL 
pathogenesis and may also influence outcome [73]. 
 
1.10 OTHER RECEPTORS IN CLL 
 
Apart from BCR and CD40, several other receptors are expressed in CLL cells. Toll 
like receptors (TLRs) recognize molecular patterns found in microbial components, 
trigger an immediate innate immune response in monocytes and granulocytes after 
infection [74] and acts as co-stimulatory signals that induce B cell maturation, 
proliferation and antibody production after pathogen recognition [75]. It has been 
shown that TLRs are expressed by CLL cells and that bacterial lipopeptides can 
protect CLL cells from spontaneous apoptosis through TLR signaling [76]. 
Expression of steroid hormone receptors has been reported in CLL. Glucocorticoid 
receptors (GR) are expressed in CLL [77], while estrogen receptor (ER) expression was 
shown in CLL in early studies, although with variable results [78-80]. In 1995 it was 
demonstrated that two different ERs exist, ERα and ERβ with opposing clinical effects 
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[81,82]. In addition several splice isoforms of ERβ have been described [83]. The most 
studied splice variant is ERβ2, which lacks ligand binding ability [84], but can form 
heterodimers with ERα inhibiting its binding to DNA. Normal B lymphocytes express 
ERβ [85], but so far no data regarding ERα and ERβ expression in CLL have been 
published. 
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2 DIAGNOSIS AND PROGNOSTIC MARKERS IN CLL 
 
2.1 DIAGNOSIS 
 
According to iwCLL guidelines the diagnosis of CLL requires an absolute B cell 
lymphocytosis (≥5 x 109/L) with a duration of at least three months with a typical 
phenotype of CD5+, CD19+, CD20dim+, CD23+ and a low level of surface 
immunoglobulin with a light chain restriction [15]. The phenotype needs to be 
confirmed by immunohistochemistry or preferably by flow cytometry. A bone 
marrow sample is not required to establish a diagnosis of CLL. 
 
2.2 CLINICAL STAGING AND THE USE OF IMAGING TECHNIQUES IN 
CLL 
 
The extremely heterogeneous course of CLL makes it difficult to predict the clinical 
course for individual patients. For more than 30 years the Rai and Binet staging 
systems have been in clinical use [86,87]. These systems are based on the presence or 
absence of lymphadenopathy, splenomegaly and bone marrow failure due to 
infiltrating CLL cells and are thus classifying patients according to the amount of 
tumor burden. However, contrary to the staging procedures in other lymphoid 
malignancies, Rai and Binet are based on clinical examination only and do not 
incorporate results from imaging techniques [88]. The use of CT scans in CLL have 
remained controversial and are not recommended for staging and response evaluation 
outside clinical studies according to the latest IWCLL guidelines [15].  
Positron emission tomography in combination with CT (PET/CT) is seldom used in 
CLL. However PET/CT can be of value to exclude transformation to a high-grade 
lymphoma and may be used to direct lymph node biopsies [89]. 
 
2.3 CYTOGENETICS 
 
Cytogenetic analysis has emerged as an important prognostic tool and findings of 
certain aberrations can predict response to therapy. In clinical praxis, the four most 
common aberrations in CLL are assessed by interphase FISH. A deletion of 13q is 
associated with a favorable course if no other aberrations are present [33], but the 
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prognosis might be related to the percentage of 13q deleted CLL cells [90]. In a 
recent study, large deletions affecting genes outside the MDR on chromosome 13 
were associated with inferior outcome [91]. It has been proposed that 13q deletions 
can be categorized into two types; Type I deletions targeting a region involving the 
MDR, whereas larger Type II deletions also include the RB1 gene locus. Type II 
deletions are more common in patients with high Rai stage and after therapy [92].  
Trisomy 12 was considered as a poor prognostic marker in early karyotyping studies 
[31], however this has not been confirmed in later studies using FISH [33,93] and 
now correlates to an intermediate prognosis. 
Deletion of 11q has been associated with extensive lymphadenopathy and a negative 
impact on progression-free and overall survival [33,93,94]. However, data from a 
recent trial indicate that a deletion of 11q22-q23 is not an adverse prognostic factor 
for patients receiving immunochemotherapy with FCR [95]. 
Deletion of 17p implies a dismal prognosis with poor response to chemotherapy 
including rituximab-containing regimens [33,95]. However, alemtuzumab can be 
effective in 17p-deleted cases [96]. 
Most patients with a 17p deletion have a TP53 mutation of the other allele [38]. Recent 
data suggest that the clinical behavior of CLL with a monoallelic TP53 inactivation due 
to mutation is similar to cases with 17p deletion [38,97]. However, a small subgroup of 
patients with TP53 abnormalities has a more indolent course [97,98]. Mutations in the 
ATM gene without corresponding deletions are also associated with impaired response 
to therapy and survival [99].  
 
2.4 MUTATIONAL STATUS 
 
IGHV gene mutational status is a prognostic factor in CLL and patients with 
unmutated CLL have an inferior outcome [25,26]. Usage of specific IGHV genes can 
also influence outcome. CLL cases with IGHV 3-21 usage have an inferior prognosis 
regardless of mutational status [68]. Cases with IGHV 4-34 usage generally have an 
indolent course [72]. Interestingly, IGHV 4-39 expression is associated with an 
increased risk for transformation to diffuse large B-cell lymphoma (DLBCL) [100]. 
Analysis of mutational status is technically challenging for clinical routine use. 
Therefore possible surrogate markers have been evaluated with CD38 and ZAP-70 
being the most studied. 
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2.5 CD38 
 
CD38 is a cell surface molecule that is expressed in approximately one-third of CLL 
cases, mainly in patients with unmutated IGHV genes and is correlated to a worse 
outcome [25]. The expression of CD38 is regulated by the tumor microenvironment 
and can be considered as an activation marker [101] and the expression level can 
change over time [102]. There is currently no consensus about which cut-off value to 
use, which limits the clinical value of CD38 analysis in CLL. 
 
2.6 ZAP-70 AND LPL 
 
Microarray studies of mutated and unmutated cases have shown that the gene 
expression pattern is similar [27]. However some genes are differentially expressed. 
ZAP-70, a SYK-family protein tyrosine kinase with a key role in signalling via the T-
cell receptor [103], is generally more expressed in unmutated cases and associated 
with an impaired prognosis [29]. Discordance between mutational status and ZAP-70 
status occurs in up to 25% of cases [104]. ZAP-70 can be analyzed by flow cytometry 
or immunohistochemistry, but lack of standardization has hampered its routine 
clinical use. However within the settings of the ERIC group, a consensual technique 
has recently been described [105]. 
High expression of LPL, is also more common in unmutated cases and predicts for a 
poor response to chemotherapy [106] and has also been proposed as a surrogate 
marker for mutational status. 
 
 
2.7 OTHER PROGNOSTIC MARKERS 
 
Several other markers have shown to be of prognostic relevance in CLL. Elevated 
thymidine kinase and β2-microglobulin in serum are associated with a worse 
prognosis [107]. Lymphocyte doubling time (LDT) has also shown to be 
prognostically important [108] and a LDT of less than six months is a criterion of 
active disease requiring therapy according to the latest iwCLL guidelines [15]. 
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3 CLINICAL MANIFESTATIONS AND TREATMENT OF 
CLL 
 
3.1 CLINICAL MANIFESTATIONS 
 
Most CLL patients are asymptomatic with a low tumor burden at diagnosis [109]. The 
most common symptom is fatigue [110]. Enlarged lymph nodes and increased 
susceptibility to infections are also common. Splenomegaly may occur, but massive 
symptomatic splenomegaly is more common later in the course of the disease. Bone 
marrow failure due to CLL infiltration with anemia, neutropenia and 
thrombocytopenia is a common reason for institution of therapy [15]. So-called B-
symptoms; weight loss, night sweats and unexplained fever, can be experienced by 
patients with advanced disease. Immunologic hematologic complications such as 
autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) 
are more common in CLL than in other lymphoid malignancies and can be the first 
symptoms of disease [111,112]. 
 
3.2 INDICATIONS FOR THERAPY 
 
Historically the therapeutic intention for CLL patients has been palliative, focusing on 
reduction of disease-related symptoms. With the emergence of more effective 
therapeutic regimens, and evidence that improved remissions are associated with 
prolonged survival [113], the goal has shifted towards obtaining CRs or even 
eradication of minimal residual disease (MRD). MRD is generally assessed by PCR 
or flow cytometry in blood or bone marrow [114].  
However more intensive therapy is often accompanied by higher toxicity and 
performance status (PS) and comorbidity must be carefully considered before therapy 
is instituted. 
Several studies have shown that alkylator-based therapies in asymptomatic CLL do 
not prolong survival [115,116]. Therefore observation (“wait and watch”) is generally 
recommended. The criteria for active disease in the iwCLL guidelines [15] are used as 
recommendations for initiation of therapy: 
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• Evidence of progressive marrow failure as manifested by the development of, 
or worsening of, anemia and/or thrombocytopenia 
• Massive (i.e., at least 6 cm below the left costal margin) or progressive or 
symptomatic splenomegaly. 
• Massive nodes (i.e., at least 10 cm in longest diameter) or progressive or 
symptomatic lymphadenopathy. 
• Progressive lymphocytosis with an increase of more than 50% over a 2-month 
period or lymphocyte doubling time (LDT) of less than 6 months. In patients 
with initial blood lymphocyte counts of less than 30*109/L LDT should not be 
used as a single parameter to define a treatment indication. 
• Autoimmune anemia and/or thrombocytopenia that is poorly responsive to 
corticosteroids or other standard therapy. 
• Constitutional symptoms, defined as any one or more of the following 
disease-related symptoms or signs: 
◦ Unintentional weight loss of 10% or more within the previous 6 months; 
◦ significant fatigue (i.e., Eastern Cooperative Oncology Group (ECOG) PS 
2 or worse; inability to work or perform usual activities); 
◦ fever higher than 38.0°C for two or more weeks without other evidence of 
infection; or 
◦ night sweats for more than 1 month without evidence of infection. 
 
3.3 CHEMOTHERAPY 
 
3.3.1 Chlorambucil 
Chlorambucil is an alkylating agent used for treatment of CLL since the 1950s and 
has until recently been a cornerstone in CLL therapy [117]. However, the complete 
remission (CR) rate for chlorambucil is low, generally below 5% [118]. Therefore, 
chlorambucil is now generally reserved for elderly patients with severe comorbidity. 
  
3.3.2 Purine analogs 
Purine analogs (fludarabine, cladribine and pentostatin) were introduced in the 1990s. 
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With these agents some patients achieved CR, which previously were seldom seen in 
CLL. Moreover, phase III trials comparing purine analogs and chlorambucil could 
demonstrate a longer progression-free survival (PFS) in the purine analog arms, but 
no improvement in overall survival [118,119]. However, in a later trial with patients 
aged more than 65 years, no benefit in PFS was seen and there was a non-significant 
trend towards shorter OS [120]. Bendamustine, a purine analog/alkylator hybrid 
agent, has also been tested against chlorambucil in a phase III trial with a higher CR 
rate, longer PFS but without an improvement in OS [121]. 
 
3.3.3 Chemotherapy combinations 
An early study compared CAP and ChOP (“French CHOP”, with a lower doxorubicin 
dose than in standard CHOP) with single-agent fludarabine. ChOP and fludarabine 
had similar response rates and showed better results than CAP, but there were no 
differences in overall survival [122]. In vitro data suggested that additional 
cytotoxicity could be obtained by combining fludarabine with the alkylating agent 
cyclophosphamide (FC) [123], since DNA repair mechanisms induced by 
cyclophosphamide, are inhibited by fludarabine [124]. In a large non-randomized trial 
with FC, a high response rate and long PFS were demonstrated [125]. 
Three randomized studies have compared FC with fludarabine, all demonstrating an 
improved CR rate and increased PFS, but no benefit in overall survival [93,126,127]. 
No phase III studies comparing single-agent fludarabine and cladribine have been 
published, but in a randomized trial comparing FC with cladribine and 
cyclophosphamide, the two combinations had similar remission rates and toxicity 
[128]. 
 
3.4 MONOCLONAL ANTIBODIES 
 
3.4.1 Alemtuzumab 
Alemtuzumab is a humanized monoclonal antibody directed against the antigen 
CD52, which is highly expressed on normal as well as malignant B and T 
lymphocytes [129]. The approved route of administration is by intravenous infusion. 
Most alemtuzumab-treated patients will be affected by a cytokine release syndrome 
[130]. These symptoms are less pronounced if alemtuzumab is given by subcutaneous 
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injections [131-133]. Alemtuzumab has been tested against chlorambucil in a phase 
III trial and showed higher OR and CR rates as well as a longer PFS, but did not 
improve OS [130].  Alemtuzumab has also been shown to be effective in patients with 
17p deletion or mutated TP53 [96] and recent guidelines recommend that 
alemtuzumab should be considered as first-line therapy in patients with 17p deletions 
[134]. 
 
3.4.2 Rituximab and ofatumumab 
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen 
expressed by mature B lymphocytes [135]. Compared to normal B lymphocytes and 
other types of indolent B cell lymphoma, expression of CD20 is lower in CLL [136]. 
In non-randomized trials low response rates was demonstrated [137]. Dose-escalation 
of rituximab led to better OR but a still a very low CR rate [138].  No randomized 
studies comparing single-agent rituximab with other agents have been reported. 
Ofatumumab is an antibody targeting a different epitope of CD20 than rituximab and 
is approved for treatment of refractory CLL by both EMA and FDA. Studies in 
previously untreated patients are ongoing [139]. 
 
3.5 CHEMOIMMUNOTHERAPY 
 
The FC + rituximab (FCR) regimen was initially evaluated in a large phase II study at 
the MDACC showing a CR rate of 70%, the highest CR rate recorded in published 
CLL trials at that time [140]. The German CLL8 phase III randomized trial between 
FC and FCR confirmed the high response rate and showed a longer PFS in the FCR 
arm. Moreover, FCR improved overall survival for the first time in a randomized 
CLL trial [95]. The patient cohort in this study consisted of relatively young 
physically fit patients with a median age of 61 years and 57% of the patients had an 
ECOG performance status of 0.  
A study comparing FCR with FC + alemtuzumab (FCA) had to be stopped due to 
increased toxicity in the FCA arm. Moreover, no significant differences in response 
rate were recorded, but a trend towards a lower CR and OR in the FCA arm [141]. A 
phase III study comparing FC and FCA with a low dose of alemtuzumab in untreated 
high-risk patients (HOVON 68) has finished recruitment, but no results have yet been 
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published. Several phase III studies comparing single-agent chlorambucil with 
addition of rituximab or ofatumumab are ongoing [139]. 
 
3.6 THERAPY AFTER RELAPSE 
 
All CLL patients will eventually relapse after therapy, and many patients will require 
multiple courses of chemotherapy during the course of the disease. Patients with 
relapsed CLL are very heterogeneous regarding age, performance status, first-line 
therapy and duration of response after that therapy. This makes it difficult to conduct 
randomized trials and to transfer the results into the general CLL population. In one 
phase III trial that compared FCR with FC in previously treated patients, FCR 
improved OR, CR and PFS but not overall survival [142]. 
Ofatumumab has shown to be active in advanced CLL. In a study with patients 
refractory to both fludarabine and alemtuzumab or fludarabine-refractory with bulky 
lymphadenopathy OR were 58% and 47% respectively [143], which led to approval 
of ofatumumab for patients refractory to fludarabine and alemtuzumab. 
 
3.7 STEM CELL TRANSPLANTATION 
 
Allogenic stem cell (alloSCT) transplantation is currently the only potentially 
curative therapeutic option in CLL. However, due to advanced age and comorbidities 
in the general CLL population, only a minority of patients are eligible for alloSCT. 
The European group for Blood and Marrow Transplantation (EBMT) has published a 
consensus document stating that alloSCT is a procedure with evidence-based efficacy 
in poor-risk CLL and proposed indications for alloSCT in CLL [144]. Criteria for 
alloSCT in biologically fit patients are: 
• Non-response or relapse < 1 year after purine analog therapy 
• Relapse < 2 years after purine analog-containing combination therapy 
• p53 abnormalities in patients with treatment indication 
Today, reduced-intensity conditioning regimens are mostly used, with less toxicity 
and lower non-relapse mortality. Long-term follow-up has shown that sustained PFS 
can be obtained in about 40% of cases [145,146]. 
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3.8 OTHER THERAPEUTIC MODALITIES 
 
Splenectomy is mainly used in CLL complicated by refractory immune cytopenias, 
but is also a therapeutic option in patients with anemia/thrombocytopenia due to 
hypersplenism or symptomatic splenomegaly not responding to other therapy [147]. 
No prospective, randomized trials have evaluated the role of splenectomy in CLL, but 
retrospective single-center case series have shown that durable responses can be 
obtained [148].  
Radiation therapy can be considered in patients with local symptoms from lymph 
nodes refractory to other therapy [149]. 
 
3.9 EMERGING THERAPIES 
 
Despite the recent advances in therapy, CLL remains incurable in the majority of 
patients and the outlook is poor for patients with refractory disease or early relapse 
after purine analogue-containing regimens [150,151]. Moreover, patients who relapse 
after several lines of therapies mostly have a deteriorated immune function and a high 
risk of infections. However, several new compounds have shown promising results in 
early phase I-II trials. 
Oblimersen is an antisense oligonucleotide that can downregulate the antiapoptotic 
Bcl-2 protein. In a phase III trial with patients who had relapsed after a fludarabine-
containing regimen were randomized between FC with or without oblimersen. The 
rate of CR/nodular PR was higher in the FC+oblimersen arm, but no differences in 
PFS were recorded [152]. 
Flavopiridol is a broad cyclin-dependent kinase inhibitor that induces apoptosis in 
CLL cells by a p53-independent pathway [153]. Early studies were disappointing in 
CLL [154]. However, with a modified administration schedule a PR rate of 45% was 
noted in a study of refractory CLL patients, including response in 5 of 12 patients 
with 17p deletions [155]. Tumor lysis syndrome (TLS) sometimes requiring 
hemodialysis was the main dose-limiting toxicity. 
Tyrosine kinase inhibitors (TKIs) have shown impressive effects in several 
malignancies [156-158]. In CLL, dasatinib, a drug approved for therapy of chronic 
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myeloid leukemia, has so far been the most studied TKI. In addition to its inhibition 
of Abl, dasatinib binds to several other tyrosine kinases of which Lyn, a member of 
the Src family, is considered to the most important in CLL [159]. In a recent phase II 
trial in heavily pretreated patients, the response rate (all PRs) was 20% [160]. 
Fostamatinib disodium, a clinically available oral Syk inhibitor, has shown an 
objective response in 6 of 11 chemotherapy-resistant SLL/CLL patients [161]. 
Lenalidomide is a derivative of thalidomide and belongs to the class of immune 
modulating drugs. It has multiple effects, such as inhibition of TNF-α synthesis, 
immune cell modulation, angiogenesis inhibition and direct antineoplastic effects 
[162], however the exact mechanism of action in CLL remains unknown. Two phase 
II trials have evaluated lenalidomide as a single-agent in patients with refractory or 
relapsed CLL. [163,164]. Reported OR rates were 47% and 32% with 9% and 7% 
CRs, respectively. Tumor flare reactions and TLS were among the main side-effects. 
Therefore, the optimal dosing of lenalidomide for CLL has not yet been established. 
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4 IMMUNE DEFECTS AND INFECTIOUS 
COMPLICATIONS IN CLL 
 
4.1 INTRODUCTION 
 
Infectious complications are a main cause of morbidity in CLL and the primary cause 
of death in 50-60% of the patients [165]. The cause of the infectious susceptibility is 
multifactorial and involves secondary hypogammaglobulinemia, T cell defects, 
neutropenia and defects in the complement pathway. Respiratory tract bacterial 
infections are the most common, but also infections of the urinary tract and the skin 
can occur [165]. The most common bacterial infectious agents are Staphylococcus 
aureus, Streptococcus pneumoniae, Hemophilus influenzae, Klebsiella pneumoniae 
and Escherichia coli. 
Purine analog-containing regimens and alemtuzumab have a pronounced T cell 
immunosuppressive effect. Therefore, with the emerging use of these agents, 
opportunistic infections like pneumocystis jiroveci, mycobacterial infections, CMV 
reactivation and fungal infections have become more common [166]. 
 
4.2 B CELL DEFECTS 
 
Immunoglobulin synthesis is decreased in many CLL patients. The mechanisms are 
not entirely clear, but CLL cells can induce apoptosis in immunoglobulin-secreting 
plasma cells through CD95/CD95L interaction [167]. Hypogammaglobulinemia was 
present in 47% of untreated patients in one study [168], but in more advanced cases 
virtually all patients have decreased immunoglobulin levels [169]. IgG, IgA and IgM 
levels are all affected [170]. 
In addition, CLL patients respond poorly to vaccines, especially polysaccharide 
vaccines [171]. However, at least in patients with early stage disease, a conjugate 
pneumococcal vaccine could provide antibody responses in 40% of the patients [172]. 
 
4.3 T CELL DEFECTS 
                                                                                                                                                                                     
The absolute numbers of T-cells are increased in CLL, especially CD8+ cells, which 
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lead to a reverse CD4/CD8 ratio and a skewed T-cell repertoire [173]. The number of 
CMV-specific CD4+ and CD8+ cells are markedly expanded and are particularly high 
in patients who receive chemotherapy, comprising up to 46% of all CD4+ cells 
[174,175].  
T regulatory cells (Treg) (CD4+ CD25+, FOXP3+), a subset with a main role in 
maintaining self-tolerance by suppressing autoreactive T-cells, are also increased in 
CLL [176]. Fludarabine therapy reduces the number of  Treg,  which may explain the 
increased risk for severe autoimmune hemolytic anemia (AIHA) and immune 
thrombocytopenia (ITP) after therapy with purine analogs [177]. 
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5 AUTOIMMUNE CYTOPENIAS 
 
5.1 INCIDENCE AND DIAGNOSTIC CHALLENGES 
 
Compared with other lymphoid malignancies, CLL is frequently associated with 
autoimmune cytopenias affecting up to 25% of CLL patients at some time during 
their disease course [177], particularly AIHA, but also ITP, PRCA and very rarely 
autoimmune granulocytopenia (AIG) [112,177,178]. AIHA is the most common 
autoimmune complication affecting 5-10% of CLL cases and CLL is the most 
common cause of  AIHA [179]. An incidence of ITP in 1-2% of CLL has been 
reported, whereas less than 1% of CLL patients develop PRCA.  
There are no strict diagnostic criteria for any of the CLL-related cytopenias. A 
diagnosis of AIHA is usually based on findings of anemia, reticulocytosis, increased 
lactate dehydrogenase (LDH) and unconjugated bilirubin levels and a positive direct 
antiglobulin test (DAT). However, the interpretation of the results is often difficult, 
since many of the findings can be disease or therapy-related. To further complicate 
the issue, at least in patients receiving chemoimmunotherapy DAT-negative AIHA is 
not uncommon [180].  
There are two main types of AIHA. In warm AIHA antibodies attach to the 
erythrocytes at 37°C, whereas in cold AIHA the antibodies directed against red blood 
cells are only active in lower temperatures. In CLL warm-antibody AIHA accounts 
for 90% of the cases, in contrast to other lymphoid malignancies [181]. Warm AIHA 
IgG antibodies are polyclonal whereas cold AIHA is mediated by monoclonal IgM 
antibodies produced by the CLL cells. [178].   
For ITP the diagnostic criteria are even less clear, since autoantibody platelet tests 
lack both specificity and sensitivity [182]. A deep and unexpected drop in 
thrombocyte count despite normal or increased numbers of megakaryocytes in bone 
marrow and the absence of hypersplenism is generally considered as ITP. In PRCA, 
there is an absence of erythropoietic precursors in the bone marrow [170]. A 
diagnosis of AIG should be considered in cases with decreased neutrophil production 
with other possible causes ruled out [178]. 
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5.2 RISK FACTORS AND PROGNOSTIC IMPORTANCE 
 
Risk factors associated with autoimmune cytopenia are advanced disease, older age, 
ZAP-70 positivity and unmutated IGHV genes [182,183].  
The association of CLL therapy and AIHA/ITP is well-known. Several reports of 
severe immune cytopenia after fludarabine monotherapy have been published 
[177,184]. Fludarabine in combination with cyclophosphamide was associated with a 
lower incidence of AIHA than fludarabine monotherapy in two studies (2.8 and 5% 
compared with 7.7% and 11%, respectively) [126,185]. A similar incidence of AIHA 
(6.5%) has been reported after FCR therapy [180]. A positive DAT before initiation of 
chemotherapy is a strong predictor for later development of AIHA, but also an 
independent negative prognostic factor in a recent clinical trial regardless of 
subsequent AIHA development [185]. Neither the Rai nor the Binet staging systems 
consider the origin of cytopenia when assigning the clinical stage for a given patient. 
However, in recent study patients with Binet C due to autoimmune cytopenias had an 
overall survival of 7.4 years compared with 3.7 years for patients with advanced stage 
due to an infiltrated bone marrow [186].  
 
5.3 THERAPY FOR AUTOIMMUNE CYTOPENIAS 
 
Therapy for AIHA or ITP in CLL has not been subject for randomized trials. 
Therefore therapeutic recommendations are largely based on expert opinions or 
consensus in national guidelines [147,187,188]. In general, first-line therapy for 
autoimmune cytopenia in patients with non-progressive CLL is steroids, in Sweden 
prednisolone 1mg/kg [147], which can induce responses in the majority of patients. 
However, durable responses are only seen in about a third of the cases [178]. 
Splenectomy can induce long-term responses in cases refractory to steroids [148]. 
However, splenectomy carries a small risk of mortality and morbidity, especially in 
elderly patients. Laparoscopic surgery is feasible in many cases [189].  
Rituximab monotherapy has provided good results in AIHA unrelated to CLL in 
several small uncontrolled retrospective studies [188], and promising results have 
also been reported in CLL-related AIHA [190]. Rituximab is usually considered as a 
therapeutic alternative in patients too frail to undergo splenectomy or in relapses after 
removal of the spleen. A recent study combining rituximab, dexamethasone and 
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cyclophosphamide showed a response rate of 89.5% in mostly pretreated patients 
[191]. Cyclosporin A and alemtuzumab are further options in refractory AIHA/ITP 
[177,192]. 
In patients with progressive CLL and concomitant AIHA/ITP data are more limited. 
Monotherapy with purine analogues, known to increase the risk of autoimmune 
cytopenia should be avoided [185]. Although combination therapy with FC or FCR 
carries a lower risk, there are currently no data to support their use in active 
autoimmune cytopenia. Therefore alternative regimens have been explored [182]. In a 
small study with R-CVP in 20 patients with autoimmune cytopenia and progressive 
CLL, the cytopenia responded in 95% of cases and the progressive CLL in 85%, but 
the duration of response was short [193]. 
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6 RICHTER’S SYNDROME 
 
Transformation of CLL to a more aggressive disease is called Richter’s syndrome 
(RS) after Maurice N Richter who published the first case in 1928 [194]. Although 
initially limited to transformation to DLBCL, the term RS has been expanded to 
include other diagnoses such as prolymphocytic leukemia, Hodgkin's lymphoma and 
multiple myeloma [195]. The incidence of RS varies significantly between studies 
with 2-15% being reported, reflecting both heterogeneity of studied CLL populations 
and different biopsy policies [196]. Median time between CLL diagnosis and RS is 
23-48 months [100,197]. Transformation should be suspected in cases with discordant 
rapid growth of lymph nodes, an unexpected rise in LDH without evidence of AIHA 
or the emergence of B-symptoms [198]. A diagnosis of RS should be made on biopsy 
material [15], since cytology cannot distinguish between CLL with numerous 
proliferation centers and transformation to DLBCL [196]. PET/CT can identify local 
transformation sites and might be useful to guide biopsies [89,199]. EBV-driven 
lymhoproliferative disease (EBV-LPD) can occur in CLL, especially after 
alemtuzumab-based therapy [200,201]. EBV-LPD can mimic RS and should be ruled 
out before a diagnosis of RS is set.  
Stereotyped BCR usage is a risk factor for RS development [202], in particular the 
IGHV 4-39 subset [100]. Additional independent risk factors in this study were lymph 
nodes ≥ 3cm in diameter, CD38 expression and absence of 13q- aberrations. 
However, in another study no such correlations were found [203]. In one study of 401 
patients, short telomere length was shown to be a risk factor for RS [45].  
The profound immunosuppression caused by treatment with purine analogs and 
alemtuzumab has raised concern about an increased risk for RS. In a retrospective 
observational study from the Mayo clinic, there were an increased number of RS 
cases after therapy with purine analogs, 5.2%, compared to 1.8% in other patients 
[203]. However, in the large LRF CLL4 trial, there were no differences in RS 
incidence between patients in the chlorambucil, F and FC arms [93]. In the phase III 
trial comparing alemtuzumab and chlorambucil there were no recorded RS cases at a 
median follow-up of 24.6 months [130].  The phase II trial of FCR at MD Anderson 
had a RS incidence of 2.5% at a follow-up of 6 years [204].  
Studies of clonal relationship between the developing DLBCL and CLL in RS have 
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shown that two types of RS may exist, clonally related to CLL or unrelated. The 
former accounts for the majority of RS cases [205,206], and have a worse prognosis 
than unrelated DLBCL cases [207]. The outcome in RS is generally worse than in de 
novo DLBCL [198,208], with a median survival of only 8 months in a study from 
MDACC including 148 RS patients over a 30-year period [209]. The CR rate was 
only 12%, but a small number of patients had long-lasting remissions for up to 15 
years. 
No randomized trials regarding RS treatment has been made, therefore there is no 
consensus on the best therapeutic approach in RS [196]. R-CHOP, which can be 
considered a standard therapy for de novo DLBCL is often used in RS, however the 
results are far from satisfactory [209,210]. A regimen with oxaliplatin, fludarabine, 
cytarabine and rituximab, OFAR, has been tested in a phase I-II trial with increasing 
doses of oxaliplatin in patients with RS or refractory CLL. Twenty RS cases were 
enrolled with a median age of 66 years. Response rate was 50% with 20% being CRs. 
However, 6-month survival rate was only 60% [211]. Patients with CLL that has 
transformed to Hodgkin’s lymphoma (HL) usually respond to standard HL therapy 
[195]. 
In follicular lymphoma transformed to DLBCL autologous stem cell transplantation 
(ASCT) is an established therapeutic alternative [212], however very little data is 
published regarding ASCT for RS [213]. AlloSCT can be a therapeutic option in 
selected patients. In the study from MDACC, seven patients who underwent alloSCT 
after obtaining at least PR after previous therapy, there was a 3-year estimated 
cumulative survival of 75% [209]. 
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7 AIMS OF THE THESIS 
 
 I. To conduct a long-term follow-up of clinical effects, infectious complications 
and risk of Richter’s transformation in CLL patients with alemtuzumab as 
first-line treatment. 
 II. To review the clinical benefit of CT scans in CLL in assessment of response. 
An additional aim was to asses if nodal and splenic tumor burden status 
detected by CT before therapy had any impact on therapy-free and overall 
survival. 
 III. To analyze the expression of the estrogen receptors ERα, ERβ1 and ERβ2 in 
blood from CLL patients and normal donors. 
 IV. To detect the chromosomal aberrations by interphase FISH; deletion of 13q14, 
11q22-q23, 17p13 and  trisomy 12 on formalin fixed, paraffin embedded 
material from splenic tissue in patients with CLL/SLL and to relate the 
findings to abnormalities in bone marrow or blood.  Additional aims were to 
analyze if cytogenetic aberrations in the spleen had prognostic relevance and 
to assess clonal evolution. 
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8 MATERIALS AND METHODS 
 
Paper I: This work is a long-term follow-up study of the previously published phase II 
trial of alemtuzumab given subcutaneously to previously untreated patients [132]. 
The Swedish Cancer Registry was used to identify historical control patients 
diagnosed with CLL during the period 1990-1997, before the aforementioned study 
started. 351 patients with CLL at four hospitals in Stockholm were identified. Patients 
(n=75), who matched the inclusion criteria for the study but received other first-line 
therapies and were not treated with alemtuzumab during the course of the disease 
were included as controls. Data were collected through case reviews. The two-sided 
Chi-square exact test was used to test differences in response rate and infections 
between study patients and historical controls. The Wilcoxon-Gehan exact test was 
used to test differences between curves representing time to treatment failure (TTTF) 
and time to Richter’s transformation. 
Paper II: Seventy-seven CLL patients included in five phase II trials, all using CT 
scans both before initiation of therapy and for response assessment [132,214-217], 
were included in the study. Assessment of response to therapy was based on 
information from the charts of the patients using the 1996 National Cancer Institute 
(NCI) Working Group criteria for CLL [218]. Since no established criteria for 
interpretation of CT scans in CLL has been published, International Working Group 
NHL criteria were used to define responses [219]. To assess the amount of nodal 
tumor burden, GELF criteria developed for follicular lymphoma were used [220]. No 
established criteria for grading of splenic enlargement in CLL exists, therefore the 
following system was used: no splenic enlargement, no palpable spleen but 
enlargement on CT (≥ 11cm in longest axis), and palpable spleen < 6 cm or > 6 cm 
under left costal margin respectively, the latter being a criterion for active disease 
(treatment indication) according to the NCI criteria [218]. The Wilcoxon-Gehan 
univariate test was used to test the possible correlation between nodal tumor burden 
status and overall and therapy-free survival. Multivariate analysis was performed 
using Cox regression. 
Paper III:  After informed consent, peripheral blood samples were obtained from 26 
CLL patients and 30 healthy donors. The diagnosis of CLL was reviewed according 
to the updated CLL guidelines [15]. PBMCs were collected from the blood samples. 
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Expression of ERα, ERβ1 and ERβ2 were analyzed by immunocytochemistry. 
Clinical data were collected by case reviews. For comparison between groups, the 
two-sided Chi-square test was used for nominal variables and Mann-Whitney U test 
for ordinal and continuous measurements. Log-rank test was used to test for 
differences in therapy-free and overall survival. 
Paper IV: Using existing registries at the Pathology department, Karolinska 
University Hospital, 62 patients with CLL (n=57) or SLL (n=5) who underwent 
splenectomy between 1989-2010 were identified. Patient data were obtained by chart 
review. Paraffin-embedded sections from spleens were obtained from the Pathology 
department, Karolinska University Hospital. Interphase FISH was used to evaluate 
chromosomal aberrations in splenic tissue and the results were compared with 
aberrations in blood and/or bone marrow before and after splenectomy, if available.  
Analyzed aberrations were deletion of 11q22-q23, 13q14, 17p13 and trisomy 12. To 
avoid false-positive results in paraffin-embedded sections due to cutting of the tissue, 
loss of the centromere in chromosome 12, an abnormality rarely occurring in CLL, 
was used as a marker to detect the amount of incomplete nuclei in the tissue sections. 
Flow cytometry data was used, or if not available, tumor involvement was assessed 
by immunohistochemistry. Spearman's rank correlation coefficient was used to 
correlate FISH results from splenic tissue with blood and bone marrow. The log-rank 
test was used to test differences between groups in time to next therapy and overall 
survival. 
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9 RESULTS, DISCUSSION AND CONCLUSIONS 
 
9.1 PAPER I 
 
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: 
long-term follow-up of clinical effects, infectious complications and risk of 
Richter transformation 
(Karlsson*, Norin* et al, Leukemia 2006;20:2204-07) (Shared first authorship) 
 
This long-term follow-up of the phase II trial studied the TTTF, the frequency of 
infectious complications and the incidence of RS in 38 patients who received 
alemtuzumab by subcutaneous injections as first-line treatment. The results were 
compared with 75 consecutive matched historical controls. Median follow-up from 
initiation of therapy to last follow-up were 64 (13-102) months and 61 (4-132) 
months in the two groups, respectively. Median TTTF for alemtuzumab-treated 
patients were 28 months compared with 17 months for the controls (p=0.07). 
Responders to alemtuzumab therapy (n=33) had a median TTTF of 32 months, 
whereas 7 patients reaching CR had a median TTTF of 77 months.  
No grade 4 infectious complications were observed in the alemtuzumab group during 
therapy. Grade 3 infections were observed in four patients (10%) and consisted of 
cytomegalovirus (CMV) reactivation that caused fever without pneumonitis (n=3) 
and Pneumocystis jiroveci pneumonia (n=1, in a patient without prophylaxis due to 
allergy to cotrimoxazole). In the matched controls, grade 3 or 4 infections were 
observed during first-line treatment in 14 patients (19%) and included fever of 
unknown origin (n=5), pneumonia (n=4, one fatal), septicemia (n=2), CMV (n=1), 
herpes zoster (n=1), dental infection (n=1) and skin infection (n=1). The difference in 
infectious complications was not statistically significant. 
During long-term unmaintained follow-up, 7/38 alemtuzumab-treated patients (18%) 
experienced 10 episodes of reversible grade 3 infections, including one symptomatic 
EBV-reactivation. No grade 4 or fatal infections were observed. In the control group 
with a shorter TTTF, the observed incidence was 8/75 (11%) including two fatal 
cases. The difference was not statistically significant.  
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In the alemtuzumab group, 6/38 (16%) developed RS compared with 9/75 (12%) in 
the other group. Median time from CLL diagnosis to transformation was 44 (20-75) 
months and 41 (14-94) months, respectively. Median time from start of first-line 
therapy to RS was 16 (3-32) months for the alemtuzumab-treated patients and 36 
months (1-84) months in the matched historical control group (not significant). 
The current work represents the first long-term follow-up of patients who have 
received first-line therapy with alemtuzumab for CLL. In the absence of randomized 
trials, retrospective historic comparisons may provide meaningful preliminary 
information. A significantly higher OR rate was observed in the alemtuzumab group 
than in the historical controls (p=0.01). The response rates and PFS and TTF in the 
alemtuzumab group were all comparable with the results from the phase III trial 
comparing alemtuzumab intravenously and chlorambucil [130]. In that study CMV 
PCR was performed weekly during therapy. Asymptomatic CMV reactivation was 
found in 52.4% whereas symptomatic infection was recorded 15.6% of the patients. 
However, only 6 (4.1%) patients had a grade 3 CMV activation compared with 3 
(8%) in this study where CMV-PCR was taken only if early symptomatic CMV was 
suspected. It therefore seems reasonable not to monitor CMV outside clinical studies, 
and this has been implemented in the Swedish national guidelines for CLL [147].  
In our study, transformation occurred in 16% of alemtuzumab-treated patients and in 
12% of the patients in the historical control group. The difference was not statistically 
significant although the incidence of RS in this study is higher than in most other 
studies [196,198]. A possible explanation might be that all cases in this study had an 
active disease requiring therapy and the relatively long follow-up period. Many of the 
patients in the alemtuzumab had advanced disease, known to increase the risk for RS. 
However it cannot be ruled out that the profound immunosuppression caused by 
alemtuzumab can be a risk factor for development of RS. In the phase III trial 
comparing alemtuzumab and chlorambucil no RS cases were observed, but the 
follow-up time is still relatively short [130].  
In conclusion, this long-term follow up study shows that despite the long-lasting 
immunosuppression, alemtuzumab appears to be effective and safe as first-line 
therapy with no apparent increase in serious infectious complications or RS compared 
to the historical control group.   
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9.2 PAPER II 
 
Tumor burden status evaluated by computed tomography scan is of prognostic 
importance in patients with chronic lymphocytic leukemia. 
(Norin et al, Med Oncol 2010;27:820-25) 
 
In this study 77 patients, previously included in five phase II trials, all using CT for 
response assessment, were evaluated regarding response rate with and without CT.  
Before therapy, enlarged lymph nodes and/or an enlarged spleen was noted by clinical 
examination in 60 (78%) and 32 (42%) patients, respectively and with CT in 64 
(83%) and 54 (70%), respectively. Massive splenomegaly (≥6 cm below left costal 
margin) was noted in 11 patients. The GELF criteria for high nodal tumor burden 
assessed by CT were fulfilled in 19 patients, with three or more nodes ≥3 cm (n = 8), 
a single node ≥7 cm (n = 2), or both (n = 9). In 11 patients (58%), the bulky lymph 
nodes and/or high nodal tumor burden were not noted by clinical examination. 
A retrospective evaluation of the response was possible for 69 of the 77 patients in the 
study. The CR rate using NCI criteria was 22% (n=15) and PR rate was 62% (n=43). 
Thus, the overall response rate (OR) was 84%. If data from the CT scans were taken 
into account, the response rates (CR, PR, and OR) dropped to 17% (12 patients), 59% 
(41 patients) and 76%, respectively. In eight patients, evaluation of response was not 
possible due to the lack of a CT evaluation in four patients, or early withdrawal from 
the study in four cases.  
The time from initiation of first-line treatment to start of next therapy (TTT) was 29 
months (1-156+) and overall survival was 70 (3-172+) months. Patients with a high 
lymphadenopathy tumor burden according to the GELF criteria had a significantly 
shorter time to next therapy, 12 months (1–78) compared to 35 months (1-156+) for 
patients with less advanced lymphadenopathy (p=0.002). In a multivariate analysis 
the two factors that had an impact on therapy-free survival were type of 
chemotherapy regimen and the degree of lymph node enlargement. There was also a 
non-significant trend for a shorter overall survival in the high nodal tumor burden 
group: 58 (9-172+) months compared to 75 (3-159+) months (p = 0.098). 
In 23 patients without splenomegaly, the time to next therapy was 36 (5-156+) 
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months and overall survival was 82 months. In 22 patients with splenomegaly on CT 
scan only, the time to next therapy was 26 (1-133) months and overall survival 70 (9-
159) months. The time to next therapy and overall survival for the 21 patients with 
palpable splenomegaly ≤ 6 cm below costal margin were 29 (1-123) and 63 (13-
172+) months and in the 11 patients with palpable splenomegaly ≥6 cm below costal 
margin 16 (2-93) and 58 (3-117) months. There was a significant trend for an 
impaired therapy-free (p=0.037) and overall survival (p=0.017) depending on the 
grade of splenomegaly. 
In recent years, the clinical approach to patients with CLL has changed remarkably. 
The quality of the remission obtained has shown to be of importance for survival 
[113]. Detection of minimal residual disease in blood and/or bone marrow has 
therefore gained a lot of attention [221]. In contrast, there has been relatively little 
interest in how tumor burden status prior to therapy affects response and survival in 
CLL. Eichhorst et al. reported that the CR rate was reduced by almost one-third when 
patients were routinely scanned with CT [126], similar to this study, where the CR 
rate was reduced by one-fifth. In a meta-analysis of three phase III trials results from 
CT scans did have a prognostic impact after administration of conventional 
chemotherapy, but not after chemoimmunotherapy [222], but it should be noted that 
CT were not mandatory and were performed in a minority of patients in the study. 
Therefore, a selection bias cannot be excluded. In contrast, in a study of clinical Rai 
stage 0 patients the presence of CT-verified abdominal lymphadenopathy correlated 
with a shorter time to progression [223]. 
In conclusion, our study shows that nodal tumor burden as well as splenomegaly 
assessed by CT before initiation of therapy predict the duration of response. 
Moreover, splenomegaly fulfilling the Cheson criteria for active disease had a 
negative impact on overall survival. The widely accepted GELF criteria for follicular 
lymphoma appear to be of value for assessment of nodal involvement in CLL and 
should be validated in a larger prospective study.  
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9.3 PAPER III 
Upregulated estrogen receptor β2 in chronic lymphocytic leukemia 
(Yakimchuk et al, submitted) 
 
In this study, estrogen receptor expression was analyzed in 26 CLL patients and 
compared with 30 healthy controls. Nuclear expression of ERα in PBMCs was found 
in a minority of both CLL patients and normal controls (in 31% and 27% respectively), 
while ERβ1 was expressed in the majority in both groups (65% and 83%) with no 
significant differences between the two groups. Moreover, ERβ1 was expressed in 
more than 50% of the cells in 11 of 17 positive CLL patients. 
A positive nuclear staining for ERβ2 was found in 18 out of 26 (69%) of CLL patients. 
In contrast, just 5 out of 30 (17%) normal controls expressed ERβ2 (p<0.05).  
Immunofluorescence double staining of PBMCs from several CLL patients showed 
expression of ERβ2 in CD19-positive B-lymphocytes but not in CD3-positive T-cells. 
ERβ2 expression was also found in the cytoplasm of CD14+ and CD68+ cells in 
several CLL patients. Large CD14+ ERβ2+ cells were surrounded by smaller ERβ2+ 
cells. In ERβ2-positive normal controls the nuclear staining for ERβ2 was observed in 
the majority of cells of different morphology representing both lymphoid and myeloid 
cells in 4 out of 5 samples. 
There were more previously treated CLL cases with low or no expression of ERβ2 
(p<0.05), but for ERβ1 no such relation was noted. A trend towards a longer time 
between diagnosis and sampling was noted for the ERβ2-low cases, 86 months 
compared to 15 months for cases expressing ERβ2 in >50% of cells (p=0.05).  
At last follow-up 14 CLL patients had required therapy after sampling. Patients with 
ERβ2 expression in more 50% of mononuclear cells (n=13) were more likely to need 
therapy (p<0.05), while patients expressing ERβ1 (n=11) in the majority of 
mononuclear cells had a significantly shorter time to therapy requirement than patients 
with less or no ERβ1 positive cells) (median 22 vs. 31 months, p<0.05). No differences 
regarding overall survival were seen between any ER expression groups.  
This study shows for the first time that the expression of nuclear ERβ2 is much more 
common in CLL cells and that ERβ2 expression is associated with co-expression of 
   33 
ERβ1 in both CLL and normal lymphocytes. Thus, most ERβ2-negative CLL patients 
lacked ERβ1 expression and the majority were also ERα−negative. 
The importance of the ERs and estrogen hormone in the immune system has been 
demonstrated in animal models [224,225]. These results indicate an important role for 
ERβ in regulating the differentiation of pluripotent hematopoietic progenitor cells. 
Expression of ERβ splice variants have been described in human immune system with 
expression of ERβ2 and ERβ5 in thymus and spleen. [226]. This is in line with our 
results in which 17% of healthy controls that expressed ERβ2.  
 In 50% of the CLL patients more than 50% of PBMCs were ERβ2-positive. The 
clinical characteristics of CLL patients in this study indicate that ERβ2 expression may 
correlate with a more indolent disease. Most of the ERβ2-positive CLL patients 
(83.3%) had not received any treatment, while 50 % of the ERβ2-negative CLL 
patients were treated. Interestingly, in CLL cases with ERβ2 expression in the majority 
of mononuclear cells only one of 13 patients had been treated compared with 6/13 (46 
%) with less or no expression of ERβ2, but patients with high expression of 
ERβ1 and/or  ERβ2 were more likely to require therapy during follow-up.   
In addition to the findings in CLL tumor cells we also detected expression of ERβ2 in 
the cytoplasm of CD68+ and CD14+ cells in three CLL patients. These cells may be 
precursors of nurse-like cells (NLC) [52]. The finding of ERβ2 expression in these cells 
indicates that ERβ2 may also play a role in the microenvironment around CLL cells.  
In conclusion, this study shows that ERβ1 is expressed in both patients and healthy controls, 
whereas ERβ2 is significantly more common in CLL. Based on our findings of 
ERβ expression in CLL cells, further investigation of the effect of estrogen and 
selective ERβ agonists might give rise to new therapeutic modalities in the future.  
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9.4 PAPER IV 
Cytogenetic abnormalities in the spleen detected by FISH in patients with 
chronic lymphocytic leukemia/small lymphocytic lymphoma 
(Norin et al, manuscript) 
In this study, cytogenetic abnormalities in splenic tissue were analyzed by FISH in 62 
patients who have underwent splenectomy for AIHA/ITP (n=31) or symptomatic 
splenomegaly (n=30) (data missing in one patient). Median age at splenectomy was 
68 (44-83) years. Chemo- and/or immunotherapy were administered to 51 of the 61 
(records missing in one patient) patients before splenectomy. Median lymphocyte 
count at splenectomy was 16.4*109/L (0.1-265.3). 
In all but two samples, FISH results from the splenic sections could be obtained. 
Cytogenetic aberrations were detected in 43 of 57 patients (75%); in 31 cases as a 
single abnormality and in 12 cases as multiple aberrations. The most common 
aberration was 13q-, detected in 60% of cases (a homozygous deletion was found in 
16%) followed by 11q- in 21%, trisomy 12 in 9% and 17q- in 7%. Spleens from 
patients with autoimmune cytopenias more commonly had more than one cytogenetic 
aberration, in 8 out of 28 cases compared to 4 out of 28 cases in the splenomegaly 
group. 
In 15 cases FISH samples from blood or bone marrow were available from time 
points both pre- and post- splenectomy, 6 additional cases had FISH data before 
splenectomy and 12 cases only after splenectomy. All patients with FISH 
abnormalities affecting >20% CLL cells in pre-splenectomy blood or bone marrow 
(n=19) were also found in the spleen, except in three cases.  
All aberrations found in splenic tissue could be detected in later blood samples, when 
available. However, in the patient who had an accessory spleen removed 8 months 
after splenectomy, an 11q- clone present in splenic tissue was not detected in the 
accessory spleen. There was a significant correlation between the amount of cells 
with 13q and 11q deletions in spleen and blood/bone marrow (p<0.01 respectively). 
In 4 of 27 cases with follow-up samples after splenectomy, new abnormalities were 
detected in blood/bone marrow.  
After a median follow-up of 43 months after splenectomy, 23 patients are alive and 
39 have died. Only one patient died within 30 days after splenectomy. In total, 33 
patients have required further therapy. Median time to next therapy was 9 (range 0-
   35 
255+) months. Patients with high-risk cytogenetic abnormalities in the spleen ((11q-) 
and/or (17p-)) (n=16) had a significantly shorter overall survival, 25 months 
compared to 58 months for patients with 13q-, trisomy 12 or a normal karyotype 
(n=21) (p<0.05). Time to next therapy was also shorter for the patients with high-risk 
cytogenetic abnormalities: 7 months compared to 19 months (p<0.01). Patients with 
13q as a single aberration (n=23) had a significantly longer median overall survival of 
85 months compared with 36 months for all other cases (n=34) (p<0.05), but there 
were no significant difference regarding time to next therapy (14 months and 9 
months respectively, p=0.35). When combining these results it was possible to discern 
three groups with different overall survival (p<0.05). Patients with more than one 
chromosomal aberration had a tendency towards a shorter overall survival (27 months 
compared to 53 months for patients with one or no aberration (p=0.17) and shorter 
time to next therapy: 7 months and 14 months respectively (p=0.08).  
Patients splenectomized due to AIHA or ITP were older, more heavily pretreated and 
had a shorter overall survival after splenectomy compared with patients who 
underwent splenectomy due to splenomegaly. There were no significant differences in 
time to next therapy. However, during a follow-up of 3 years or longer, 10 out of 30 
patients who had splenomegaly as indication for surgery have not required any further 
therapy and 4 patients are alive with stable indolent disease ≥ 10 years after 
splenectomy. In the AIHA/ITP group only 5 out of 31 patients did not receive any 
additional chemotherapy for at least 3 years. 
There are few studies regarding cytogenetic abnormalities in CLL in other tissues 
than blood and bone marrow. To our knowledge there is no published FISH data on 
tissue sections in CLL/SLL. However a study on fine needle aspirations from lymph 
nodes in CLL and SLL has been published [227] and demonstrated a short overall 
survival associated with deletion of 11q or 17p. 
By analyzing cytogenetic aberrations in the spleen in patients with CLL/SLL we can 
now define three groups with different overall survival: deletion of 13q as a single 
aberration had a relatively favorable course, followed by patients with trisomy 12 or 
normal karyotype, whereas patients with a high-risk karyotype had a dismal 
prognosis.  
In general, FISH results on splenic tissue correlated well to previous blood/bone 
marrow samples and CE was a relatively rare event compared to previous studies 
[43,44]. However, it should be noted that by setting the cut-off to 40%, necessary to 
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avoid false-positive results due to tissue cutting and incomplete nuclei, smaller clones 
of 11q- and 17p- will not be detected, and this might therefore lead to an 
underestimation of CE in this study. 
In our material most of the patients were in Binet C stage. Neither the Rai nor the 
Binet staging systems consider the origin of anemia or thrombocytopenia when 
assigning the stage. In a recent study, patients with Binet C stage due to autoimmune 
cytopenia had a longer survival than patients with advanced stage due to bone 
marrow infiltration [186]. Although not confirmed, it seems reasonable to suggest that 
cytopenia due to consumption in an enlarged spleen might also be a favorable 
subgroup of Binet stage C patients which might explain the apparently long therapy-
free survival in some patients. 
In conclusion, cytogenetic abnormalities in splenic CLL tissue are prognostically 
important. In our study of splenectomized patients, aberrations detected by FISH on 
paraffin-embedded spleen sections have an impact on overall survival and therapy-
free survival. Clonal evolution was only detected in a few patients during long-term 
follow-up. In selected patients splenectomy can induce very long remissions. 
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10 FUTURE PERSPECTIVES 
 
During the past decade there has been a significant increase in our knowledge of 
CLL. We have begun to understand the underlying mechanisms in the development of 
CLL and its predecessor MBL. Many new prognostic markers have been developed 
and can to a certain extent predict response to therapy. New treatment regimens have 
led to improved responses and long-term remissions are now common. 
However despite the recent advancements, there are still many issues to be solved in 
the management of CLL. Standard CLL therapy is still not curative and most patients 
will eventually succumb to the disease. Several new phase III studies have shown 
impressive remission rates and for the first time a prolonged survival was 
demonstrated in one trial [95]. Long-term follow-up results are needed to confirm the 
results. The management of advanced disease has been far less studied, and with the 
exception of alemtuzumab, there are no good approved therapy alternatives for 
patients with 17p deletions [96]. In the first paper of this thesis we did a long-term 
follow up of the results from the first study with subcutaneous alemtuzumab as 
primary therapy confirming the good results [132], but also presented data regarding 
infectious complications and Richter’s syndrome.  
RS is a well-recognized complication to CLL, but data presented are mainly in the 
form of case series from single-centers [209]. With the emergence of national and/or 
European registries for CLL, it should be possible to present multi-center results for 
frequently used therapies such as R-CHOP-14 and also to finally answer the question 
whether modern immunosuppressive chemo- and/or immunotherapy can cause an 
increase in RS incidence. 
Therapy for AIHA and ITP in CLL patients has not been investigated in any formal 
trial, but proper use of registry data will add a lot of information. Since both 
alemtuzumab and rituximab have provided good results in cases series [190,192], 
phase I/II trials with rituximab and/or alemtuzumab for autoimmune cytopenias can 
hopefully be initiated. 
The new prognostic markers should be tested in clinical trials and it is also important 
to continuously evaluate the role of existing prognostic markers. In our second paper 
in this thesis we provided data regarding the use of CT for evaluation of remission 
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and assessment of tumor burden in CLL. Several studies have now presented data 
regarding the use of CT, but with conflicting results [222,223,228], probably due to 
differences in patient material, given therapy and selection bias. Hopefully this 
outstanding question can be answered by examining results from phase III trials in 
which CT scans are mandatory. 
FISH has emerged as the most used prognostic marker in CLL. However, the study 
that established FISH as a prognostic tool is largely based on results from untreated 
patients [33]. Ideally, the results should be reproduced by studying the incidence and 
relevance of cytogenetic aberrations in more advanced disease. Given the emerging 
knowledge about the importance of proliferation centers in CLL [58], comparing the 
interphase FISH from blood and bone marrow with lymphoid tissues might provide 
interesting results regarding clonal selection and evolution in different compartments. 
In our last study in the thesis, we showed that detection of common CLL aberrations 
in paraffin-embedded material is feasible and can provide prognostic information. 
Despite the recent therapeutic advances in CLL new drugs are needed. Our findings 
that ERβ1 is expressed and ERβ2 is upregulated in CLL might provide a new target 
for therapy. ERβ agonists might be potential agents in the treatment of CLL, but 
monitoring for immunosuppressive effects might be necessary given the high rate of 
ERβ1 expression in normal lymphocytes. Genistein is one of the main isoflavones 
derived from soybeans with high binding affinity for ERβ1. Several studies have 
shown a suppressive effect of genistein on CLL and lymphoma cells in vitro alone or 
in combination with fludarabine [229,230]. Based on our findings of ERβ expression 
in CLL cells, studies of the effect of estrogen and selective ERβ agonists in CLL 
might give rise to new therapeutic modalities in the future. 
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